These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 30206110)

  • 1. The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.
    O'Leary B; Cutts RJ; Liu Y; Hrebien S; Huang X; Fenwick K; André F; Loibl S; Loi S; Garcia-Murillas I; Cristofanilli M; Huang Bartlett C; Turner NC
    Cancer Discov; 2018 Nov; 8(11):1390-1403. PubMed ID: 30206110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
    Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
    Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
    Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH
    Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
    Fribbens C; O'Leary B; Kilburn L; Hrebien S; Garcia-Murillas I; Beaney M; Cristofanilli M; Andre F; Loi S; Loibl S; Jiang J; Bartlett CH; Koehler M; Dowsett M; Bliss JM; Johnston SR; Turner NC
    J Clin Oncol; 2016 Sep; 34(25):2961-8. PubMed ID: 27269946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
    O'Leary B; Cutts RJ; Huang X; Hrebien S; Liu Y; André F; Loibl S; Loi S; Garcia-Murillas I; Cristofanilli M; Bartlett CH; Turner NC
    J Natl Cancer Inst; 2021 Mar; 113(3):309-317. PubMed ID: 32940689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
    Darrigues L; Pierga JY; Bernard-Tessier A; Bièche I; Silveira AB; Michel M; Loirat D; Cottu P; Cabel L; Dubot C; Geiss R; Ricci F; Vincent-Salomon A; Proudhon C; Bidard FC
    Breast Cancer Res; 2021 Mar; 23(1):31. PubMed ID: 33676547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
    Rugo HS; Turner NC; Finn RS; Joy AA; Verma S; Harbeck N; Masuda N; Im SA; Huang X; Kim S; Sun W; Iyer S; Schnell P; Bartlett CH; Johnston S
    Eur J Cancer; 2018 Sep; 101():123-133. PubMed ID: 30053671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
    Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Ohtani S; Shimizu C; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M
    Breast Cancer; 2021 Mar; 28(2):335-345. PubMed ID: 33085032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.
    Takeshita T; Iwamoto T; Niikura N; Watanabe K; Kikawa Y; Kobayashi K; Iwakuma N; Okamura T; Tada H; Ozaki S; Okuno T; Toh U; Yamamoto Y; Tsuneizumi M; Ishiguro H; Masuda N; Saji S
    ESMO Open; 2024 Apr; 9(4):102385. PubMed ID: 38387111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
    Turner NC; Finn RS; Martin M; Im SA; DeMichele A; Ettl J; Diéras V; Moulder S; Lipatov O; Colleoni M; Cristofanilli M; Lu DR; Mori A; Giorgetti C; Iyer S; Bartlett CH; Gelmon KA
    Ann Oncol; 2018 Mar; 29(3):669-680. PubMed ID: 29342248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
    Turner NC; Liu Y; Zhu Z; Loi S; Colleoni M; Loibl S; DeMichele A; Harbeck N; André F; Bayar MA; Michiels S; Zhang Z; Giorgetti C; Arnedos M; Huang Bartlett C; Cristofanilli M
    J Clin Oncol; 2019 May; 37(14):1169-1178. PubMed ID: 30807234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.
    Masuda N; Inoue K; Nakamura R; Rai Y; Mukai H; Ohno S; Hara F; Mori Y; Hashigaki S; Muramatsu Y; Nagasawa T; Umeyama Y; Huang X; Iwata H
    Int J Clin Oncol; 2019 Mar; 24(3):262-273. PubMed ID: 30392115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
    Diéras V; Rugo HS; Schnell P; Gelmon K; Cristofanilli M; Loi S; Colleoni M; Lu DR; Mori A; Gauthier E; Huang Bartlett C; Slamon DJ; Turner NC; Finn RS
    J Natl Cancer Inst; 2019 Apr; 111(4):419-430. PubMed ID: 30032196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.
    Harbeck N; Iyer S; Turner N; Cristofanilli M; Ro J; André F; Loi S; Verma S; Iwata H; Bhattacharyya H; Puyana Theall K; Bartlett CH; Loibl S
    Ann Oncol; 2016 Jun; 27(6):1047-1054. PubMed ID: 27029704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
    Turner NC; Slamon DJ; Ro J; Bondarenko I; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; André F; Puyana Theall K; Huang X; Giorgetti C; Huang Bartlett C; Cristofanilli M
    N Engl J Med; 2018 Nov; 379(20):1926-1936. PubMed ID: 30345905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine.
    Schiff R; Jeselsohn R
    Cancer Discov; 2018 Nov; 8(11):1352-1354. PubMed ID: 30385523
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
    Berger F; Marce M; Delaloge S; Hardy-Bessard AC; Bachelot T; Bièche I; Pradines A; De La Motte Rouge T; Canon JL; André F; Arnould L; Clatot F; Lemonnier J; Marques S; Bidard FC;
    BMJ Open; 2022 Mar; 12(3):e055821. PubMed ID: 35241469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
    Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
    Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.